Skip to main content
Clinical Trials/NCT01154309
NCT01154309
Completed
Phase 1

Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders

RAND1 site in 1 country73 target enrollmentSeptember 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Depression
Sponsor
RAND
Enrollment
73
Locations
1
Primary Endpoint
Reductions in depressive symptoms as measured by the BDI II
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The investigators will adapt and test an existing treatment (group CBT for depression) for use in outpatient substance use treatment settings as delivered by trained substance use counselors. The investigators expect that treatment will lead to improved depression and substance use outcomes.

Detailed Description

Aim 1. To adapt an existing group therapy (CBT for depression), creating a manualized treatment and accompanying implementation measures and tools for use with clients with persistent depressive symptoms and AOD disorders and to obtain preliminary assessments of the treatment from patient and provider perspectives. Aim 2. To conduct a pilot test of the revised treatment in which we (a) demonstrate that when the therapy is implemented with fidelity, clinically significant reductions in depressive symptoms and AOD use occur; (b) estimate the likely effect size; and (c) investigate the underlying mechanisms of change, including both cognitive-behavioral and group processes and their relationship to depression and AOD treatment outcomes.

Registry
clinicaltrials.gov
Start Date
September 2006
End Date
September 2009
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
RAND
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Enrolled in outpatient substance abuse program
  • BDI II score \>13
  • Probable alcohol or substance use problem

Exclusion Criteria

  • Cognitive impairment (Short Blessed \> 10)
  • Probably bipolar or schizophrenic disorder

Outcomes

Primary Outcomes

Reductions in depressive symptoms as measured by the BDI II

Time Frame: Post treatment

Reductions in AOD use

Time Frame: Post treatment

Study Sites (1)

Loading locations...

Similar Trials